Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.

Yuan Z, Yi X, Zhang J, Cheng S, Zhuo R, Li F.

Chem Commun (Camb). 2013 Jan 28;49(8):801-3. doi: 10.1039/c2cc37798e.

PMID:
23235958
2.

Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.

Xu Z, Wang D, Xu S, Liu X, Zhang X, Zhang H.

Chem Asian J. 2014 Jan;9(1):199-205. doi: 10.1002/asia.201301030. Epub 2013 Oct 17.

PMID:
24136878
3.

A pH-responsive prodrug for real-time drug release monitoring and targeted cancer therapy.

Li SY, Liu LH, Jia HZ, Qiu WX, Rong L, Cheng H, Zhang XZ.

Chem Commun (Camb). 2014 Oct 14;50(80):11852-5. doi: 10.1039/c4cc05008h.

PMID:
25145493
4.

Co-delivery of 10-hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy.

Zhang Y, Xiao C, Li M, Chen J, Ding J, He C, Zhuang X, Chen X.

Macromol Biosci. 2013 May;13(5):584-94. doi: 10.1002/mabi.201200441. Epub 2013 Feb 18.

PMID:
23420692
5.

Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms.

Greenwald RB, Pendri A, Conover C, Gilbert C, Yang R, Xia J.

J Med Chem. 1996 May 10;39(10):1938-40. No abstract available.

PMID:
8642549
6.

Synthesis and activity of a folate targeted monodisperse PEG camptothecin conjugate.

Henne WA, Kularatne SA, Hakenjos J, Carron JD, Henne KL.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5810-3. doi: 10.1016/j.bmcl.2013.08.113. Epub 2013 Sep 7.

PMID:
24064501
7.

Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery.

Hu X, Hu J, Tian J, Ge Z, Zhang G, Luo K, Liu S.

J Am Chem Soc. 2013 Nov 20;135(46):17617-29. doi: 10.1021/ja409686x. Epub 2013 Nov 7.

PMID:
24160840
8.

Combating the drug resistance of cisplatin using a platinum prodrug based delivery system.

Min Y, Mao CQ, Chen S, Ma G, Wang J, Liu Y.

Angew Chem Int Ed Engl. 2012 Jul 2;51(27):6742-7. doi: 10.1002/anie.201201562. Epub 2012 May 25. No abstract available.

PMID:
22639083
9.

Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.

Legigan T, Clarhaut J, Renoux B, Tranoy-Opalinski I, Monvoisin A, Berjeaud JM, Guilhot F, Papot S.

J Med Chem. 2012 May 10;55(9):4516-20. doi: 10.1021/jm300348r. Epub 2012 Apr 30.

PMID:
22515366
10.

Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug.

Huang S, Fang R, Xu J, Qiu S, Zhang H, Du J, Cai S.

J Drug Target. 2011 Aug;19(7):487-96. doi: 10.3109/1061186X.2010.511225. Epub 2011 Feb 2.

PMID:
21284542
11.

A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery.

Du C, Deng D, Shan L, Wan S, Cao J, Tian J, Achilefu S, Gu Y.

Biomaterials. 2013 Apr;34(12):3087-97. doi: 10.1016/j.biomaterials.2013.01.041. Epub 2013 Jan 29.

PMID:
23374705
12.

Tumor-targeted and activated bioconjugates for improved camptothecin delivery.

Paranjpe PV, Stein S, Sinko PJ.

Anticancer Drugs. 2005 Aug;16(7):763-75.

PMID:
16027527
13.
14.

Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.

Fan J, Fang G, Wang X, Zeng F, Xiang Y, Wu S.

Nanotechnology. 2011 Nov 11;22(45):455102. doi: 10.1088/0957-4484/22/45/455102. Epub 2011 Oct 21.

PMID:
22019849
15.

Poly(ethylene glycol) versus dendrimer prodrug conjugates: influence of prodrug architecture in cellular uptake and transferrin mediated targeting.

Aher N, Banerjee S, Bhansali S, Yadav R, Shidore M, Mhaske S, Chaudhari R, Asai S, Jalota-Badhwar A, Khandare J.

J Biomed Nanotechnol. 2013 May;9(5):776-89.

PMID:
23802407
16.

Oligonucleotides--assembled Au nanorod-assisted cancer photothermal ablation and combination chemotherapy with targeted dual-drug delivery of Doxorubicin and Cisplatin prodrug.

Shanmugam V, Chien YH, Cheng YS, Liu TY, Huang CC, Su CH, Chen YS, Kumar U, Hsu HF, Yeh CS.

ACS Appl Mater Interfaces. 2014 Mar 26;6(6):4382-93. doi: 10.1021/am5000905. Epub 2014 Mar 5.

PMID:
24559392
17.

Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.

Zhan F, Chen W, Wang Z, Lu W, Cheng R, Deng C, Meng F, Liu H, Zhong Z.

Biomacromolecules. 2011 Oct 10;12(10):3612-20. doi: 10.1021/bm200876x. Epub 2011 Sep 21.

PMID:
21905663
18.

A macromolecular prodrug strategy for combinatorial drug delivery.

Li NN, Lin J, Gao D, Zhang LM.

J Colloid Interface Sci. 2014 Mar 1;417:301-9. doi: 10.1016/j.jcis.2013.11.061. Epub 2013 Dec 1.

PMID:
24407691
19.

Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.

Wang H, Zhao Y, Wu Y, Hu YL, Nan K, Nie G, Chen H.

Biomaterials. 2011 Nov;32(32):8281-90. doi: 10.1016/j.biomaterials.2011.07.032. Epub 2011 Jul 31.

PMID:
21807411
20.

Development of efficient acid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell.

Calderón M, Welker P, Licha K, Fichtner I, Graeser R, Haag R, Kratz F.

J Control Release. 2011 May 10;151(3):295-301. doi: 10.1016/j.jconrel.2011.01.017. Epub 2011 Jan 21.

PMID:
21256902

Supplemental Content

Support Center